Oxygen Containing Hetero Ring Patents (Class 514/449)
  • Patent number: 11020370
    Abstract: The present invention provides a pharmaceutical composition for oral administration, comprising (a) 4 to 40% by weight of a taxane, (b) 10 to 30% by weight of a medium chain triglyceride, (c) 30 to 70% by weight of monooleoyl glycerol, (d) 5 to 30% by weight of a surfactant, and (e) 10 to 30% by weight of polyoxyl glyceryl fatty acid ester and a process for preparing the same.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: June 1, 2021
    Assignee: DAE HWA PHARMA. CO., LTD.
    Inventors: In-Hyun Lee, Min-Hee Son, Yeong-Taek Park, Han-Koo Lee
  • Patent number: 11001840
    Abstract: The present invention relates to the composition of a nanoparticle based on a magnesium salt, and methods of drug delivery using the nanoparticle. A preferred embodiment uses magnesium phosphate, with or without a shell to deliver aiRNA and/or siRNA. The nanoparticles of the present invention are also effective when administered orally.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: May 11, 2021
    Assignee: 1GLOBE HEALTH INSTITUTE LLC
    Inventors: Chiang Jia Li, Youzhi Li, Keyur Gada, Xiaoshu Dai
  • Patent number: 10980891
    Abstract: The present technology relates generally to oligolactic acid conjugates of paclitaxel, rapamycin, selumetinib, and other anticancer agents, micelle compositions containing such conjugates and methods of preparing and using such compositions to treat various cancers. Specifically, there are provided oligolactic acid conjugates wherein the oligolactic acid comprises 2 to 24 lactic acid subunits and is attached through an ester linkage to the oxygen of the 7-hydroxyl of the paclitaxel or paclitaxel derivative, the 40-hydroxyl of the rapamycin or rapamycin derivative, and the 2?-hydroxyl of the selumetinib or selumetinib derivative. Compositions comprising water and a micelle comprising a polylactic acid-containing polymer and the oligolactic acid conjugate may be readily prepared. Methods of inhibiting or killing cancer cells and treating paclitaxel, rapamycin, and/or selumetinib cancers are also provided.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: April 20, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Glen S. Kwon, Yu Tong Tam
  • Patent number: 10974022
    Abstract: Provided is a nasal implant assembly comprising a hollow implant having a distal end and a proximal end, the distal end configured to have a segment deposited with magnetic particles; and a medical syringe configured to be attachable to the proximal end of the hollow implant and also configured to be capable of retaining and transporting a magnetically active fluid composition through the implant to a nasal cavity of a subject. Also provided is a method of treating chronic rhinosinusitis in a subject, the method comprising the steps of positioning a nasal implant having magnetic particles into a nasal cavity; loading a medical syringe with a magnetically active fluid composition; and transporting the loaded magnetically active fluid composition to the nasal cavity to treat chronic rhinosinusitis.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: April 13, 2021
    Assignee: Gyrus Acmi, Inc.
    Inventor: Thomas J. Holman
  • Patent number: 10888553
    Abstract: There is disclosed a platinum ion chelating dipyridoxyl compound according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein the dipyridoxyl compound is uncoordinated or coordinated with a metal ion which is not a transition metal, for prevention or treatment of chemotherapy drug induced peripheral sensory neuropathy in a patient, wherein the chemotherapy drug comprises platinum ions. An example of such a chemotherapy drug is oxaliplatin. The drawbacks of previous metal complexed compounds containing manganese ions are eliminated. A more frequent use of the drug is possible since the problem in the prior art with accumulated manganese neurotoxicity is eliminated. The compounds can be administered both temporally and spatially separately from chemotherapy.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: January 12, 2021
    Assignee: KARLSSON-TUNER INVEST AS
    Inventors: Jan-Olof G Karlsson, Per Jynge, Rolf G G Andersson
  • Patent number: 10888633
    Abstract: A freshening composition is provided. The composition includes at least one particle, and an aqueous carrier. The composition includes a polysaccharide system having a first polysaccharide and a second polysaccharide. The first polysaccharide is xanthan gum and the second polysaccharide is selected from the group consisting of konjac gum, locust bean gum, and combinations thereof. The composition may include an unencapsulated perfume.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: January 12, 2021
    Assignee: The Procter & Gamble Company
    Inventors: Matthew Lawrence Lynch, Carla Jean Colina, Steven Anthony Horenziak, Brandon Philip Illie, Yonas Gizaw, Yiping Sun
  • Patent number: 10842770
    Abstract: Non-aqueous taxane pro-emulsion formulations are provided. Pro-emulsion formulations of embodiments of the invention include a taxane, an oil component, a surfactant component and, optionally, a non-aqueous solvent component. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: November 24, 2020
    Assignee: Teikoku Pharma USA, Inc.
    Inventor: Kiichiro Nabeta
  • Patent number: 10835511
    Abstract: A pharmaceutical composition comprises a taxane (e.g., paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, and/or tesetaxel) in a mixture of first and second surfactants. The absorption of the taxane is increased from the pharmaceutical composition is greater than the sum of the absorption of docetaxel from either the first or the second surfactant. The increase in absorption is especially enhanced when the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 by weight, and the total surfactant weight does not exceed 98% of the total weight. Polysorbate 80, polysorbate 20, and caprylocaproyl polyoxylglycerides serve as suitable first surfactants, and polysorbate 80 or polyethyoxylated castor oil serve as suitable second surfactants. The stability of the pharmaceutical composition may be enhanced by further including a stabilizer (e.g., citric acid and/or ascorbic acid).
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: November 17, 2020
    Assignee: Athenex HK Innovative Limited
    Inventors: Denise S. B. Chan, Ming Tsung Lee, Weng Li Yoon, Johnson Yiu-Nam Lau
  • Patent number: 10755078
    Abstract: Provided herein are methods for analysis of target cells on a population or individual basis, including before and after contact with a stimulus in order to determine the effect of such stimulus on the target cells. Also provided are devices for performing such methods. The analysis methods involve identifying and measuring or tracking morphological changes that occur in target cells over a period of time. Tracking is accomplished using imaging systems capable of imaging target cells individually over a period of time either continuously or at discrete intervals of time.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: August 25, 2020
    Assignees: President and Fellows of Harvard College, Nikon Corporation
    Inventors: Lee L. Rubin, Yasujiro Kiyota, Chieko Nakada, Keiichi Niikura, Kathleen L. Pfaff
  • Patent number: 10684294
    Abstract: Provided herein are improved fluorogenic compounds and probes that can be used as reagents for measuring, detecting and/or screening hypochlorous acid or hydroxyl radical. The fluorogenic compounds of the invention can produce fluorescence colors, such as green, yellow, red, or far-red. Also provided herein are fluorogenic compounds for selectively staining hypochlorous acid or hydroxyl radical in the mitochondria of living cells. Provided also herein are methods that can be used to measure, directly or indirectly, the presence and/or amount of hypochlorous acid or hydroxyl radical in chemical samples and biological samples such as cells and tissues in living organisms. Also provided are high-throughput screening methods for detecting or screening hypochlorous acid or hydroxyl radical or compounds that can increase or decrease the level of hypochlorous acid or hydroxyl radical in chemical and biological samples.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: June 16, 2020
    Assignee: THE UNIVERSITY OF HONG KONG
    Inventors: Dan Yang, Jun Hu, Nai-Kei Wong, Xiaoyu Bai
  • Patent number: 10682330
    Abstract: In order to reduce the side effects of paclitaxel derivatives having excellent anti-cancer effects, an attempt was made to produce a liposome encapsulating paclitaxel derivatives such as paclitaxel monoglycosides and docetaxel monoglycosides. However, the introduction efficiency of paclitaxel derivatives, etc., into a liposome was poor, and this technique was not developed to a practical level. The present invention provides a method for producing a liposome encapsulating a paclitaxel monoglycoside and/or a docetaxel monoglycoside, and having an antibody specifically recognizing a cancer cell, the method comprising a step of bringing a liposome encapsulating a polyoxyethylene ester derivative, a lower alcohol, and a buffer or water into contact with a solution in which a paclitaxel monoglycoside and/or a docetaxel monoglycoside is dissolved in an alkylene glycol-containing buffer or water.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: June 16, 2020
    Assignees: ENSUIKO SUGAR REFINING CO., LTD., HIROKI HAMADA, YOSHIO SHIMIZU, NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
    Inventors: Hiroki Hamada, Ichiro Fujiwara, Masaharu Seno, Tomonari Kasai, Tsukasa Shigehiro, Masaharu Murakami, Katsuhiko Mikuni
  • Patent number: 10675296
    Abstract: The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: June 9, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventor: Nate Larson
  • Patent number: 10610565
    Abstract: Therapeutic methods including administration of cyclosporin to an eye of a mammal in combination with administration of a therapeutically active agent effective for treatment of a cancer to said mammal to treat an ocular condition associated with the use of said therapeutically active agent are disclosed herein.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: April 7, 2020
    Assignee: Allergan, Inc.
    Inventors: Gregg Feinerman, Neil Barth, Rhett M. Schiffman, Pamela S. Barnett
  • Patent number: 10561766
    Abstract: According to the invention there is provided inter alia a medical device for delivering a paclitaxel to a tissue, the device the device having a coating layer applied to a surface of the device, the coating layer comprising components i), ii) and iii), wherein component i) is a therapeutic agent which is paclitaxel; and component ii) is urea or a pharmaceutically acceptable salt thereof, or a urea derivative or a pharmaceutically acceptable salt thereof; and component iii) is succinic acid, glutaric acid or caffeine, or a pharmaceutically acceptable salt of any one thereof.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: February 18, 2020
    Assignee: W. L. Gore & Associates, Inc.
    Inventors: Per Antoni, Karin Leontein, Mei Li, Robert L. Cleek, Paul D. Drumheller
  • Patent number: 10557850
    Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: February 11, 2020
    Assignee: THE REGENTS OF UNIVERSITY OF MICHIGAN
    Inventors: Max S. Wicha, Christophe Ginestier
  • Patent number: 10550093
    Abstract: The invention includes taxoid compounds represented by the formula: wherein: R1 represents a methyl group or a fluorine; R2 represents an alkyl or alkenyl group having one to six carbon atoms; or a cycloalkyl or cycloalkenyl group having three to seven ring carbon atoms; R3 represents an alkyl, alkenyl, dialkylamino, alkylamino, or alkoxy group having one to six carbon atoms; a cycloalkyl or cycloalkenyl group having three to seven ring carbon atoms; an aryl group having six to eighteen ring carbon atoms; or a heteroaryl group having three to seventeen ring carbon atoms; R4 represents hydrogen or a methyl group; and X represents hydrogen or fluorine.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: February 4, 2020
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Iwao Ojima, Changwei Wang, Xin Wang
  • Patent number: 10525113
    Abstract: Disclosed in the present invention is micellar polypeptide vaccine having pegylated phospholipid as carrier. The vaccine can prevent or treat tumors or can be used as combination formulation with anti-cancer activity formulation. The micellar polypeptide vaccine is formed of self-assembling pegylated phospholipid (PEG-PE) and antigenic polypeptides, the pegylated phospholipid being compound formed of polyethylene glycol (hydrophilic blocks) covalently bonded to nitrogenous bases on phospholipid molecule (hydrophobic blocks). The particle diameter of the micellar vaccine is 10-100 nm, and the antigenic polypeptides carried therein are polypeptides of 5-100 amino acids. The micellar polypeptide vaccine may also contain immunoadjuvant.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: January 7, 2020
    Assignee: SHANGHAI TIANHUI CHEMICAL PHARMACEUTICAL CO. LTD
    Inventors: Wei Liang, Yan Qin
  • Patent number: 10525037
    Abstract: The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: January 7, 2020
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Jin Wang, Jianjun Chen, Duane D. Miller, Wei Li
  • Patent number: 10517886
    Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: December 31, 2019
    Assignee: ASTEX PHARMACEUTICALS, INC.
    Inventors: Rajashree Joshi-Hangal, Chunlin Tang, Sanjeev Redkar, Harish Ravivarapu
  • Patent number: 10456477
    Abstract: The present technology relates generally to oligolactic acid conjugates of paclitaxel, rapamycin, selumetinib, and other anticancer agents, micelle compositions containing such conjugates and methods of preparing and using such compositions to treat various cancers. Specifically, there are provided oligolactic acid conjugates wherein the oligolactic acid comprises 2 to 24 lactic acid subunits and is attached through an ester linkage to the oxygen of the 7-hydroxyl of the paclitaxel or paclitaxel derivative, the 40-hydroxyl of the rapamycin or rapamycin derivative, and the 2?-hydroxyl of the selumetinib or selumetinib derivative. Compositions comprising water and a micelle comprising a polylactic acid-containing polymer and the oligolactic acid conjugate may be readily prepared. Methods of inhibiting or killing cancer cells and treating paclitaxel, rapamycin, and/or selumetinib cancers are also provided.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: October 29, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Glen S. Kwon, Yu Tong Tam
  • Patent number: 10363219
    Abstract: The present invention belongs to the field of bio-pharmaceutical material preparation technology, and relates to a preparation method of albumin nanoparticle carrier entrapping taxane-typed drug. This preparation method rapidly forms nanoparticle solution of albumin entrapping taxane-typed drug under room temperature by adding solvent as the medium. Next, by the second time of freeze-drying, stable powder of albumin nanoparticles entrapping taxane-typed drug is obtained. The final freeze-dried powder only includes two components: albumin and taxane-typed drug. The particles are in regular spherical shape, and the diameter of particle is less than 100 nm. The present invention has high drug loading ratio and entrapment efficiency. The experiment of releasing in vitro shows that the present invention has a good slow-release effect. Taxane-typed drug nanoparticles provided by the present invention improves the safety and compliance of this type of reagent.
    Type: Grant
    Filed: May 20, 2017
    Date of Patent: July 30, 2019
    Assignee: Zhejiang Academy of Forestry
    Inventors: Ru Fang, Shaozong Yang, Hua Qian, Yanbin Wang
  • Patent number: 10286079
    Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: May 14, 2019
    Assignees: The Regents of the University of California, Vybyl Holdings, Inc.
    Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L. M. LeGuyader, Paul A. Bertin
  • Patent number: 10278946
    Abstract: The present invention relates to a stable liquid formulation of cabazitaxel. The formulation comprises cabazitaxel and at least one solubilizer. Typically, formulations are in the form of ready-to-use solutions or concentrates.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: May 7, 2019
    Assignee: EMCURE PHARMACEUTICALS LIMITED
    Inventors: Hiren Pravinbhai Patel, Haresh Ishwarbhai Patel, Arpan Suresh Chudasama, Neha Manubhai Patel, Deepak Pragjibhai Gondaliya, Mukund Keshav Gurjar, Samit Satish Mehta
  • Patent number: 10251860
    Abstract: Disclosed herein are embodiments of a method of accelerating bone healing in a subject in need thereof, comprising administering to the subject a compound disclosed here. The method may further comprise selecting or identifying a subject that has bone damage, or is a risk of developing bone damage. The compound may be administered after bone damage has occurred, or it may be administered prophylactically. The compound may be administered to a subject that has not and/or will not be exposed to radiation. In other embodiments, the subject has been and/or will be exposed to radiation.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: April 9, 2019
    Assignees: University of Pittsburgh—of the Commonwealth System of Higher Education, The Brigham and Women's Hospital, Inc.
    Inventors: Michael W. Epperly, Joel S. Greenberger, Peter Wipf, Julianne Glowacki
  • Patent number: 10206972
    Abstract: An anti-vascular diseases and antitumor pharmaceutical composition is provided in the present invention, and it includes effective ingredients including bleomycin antitumor antibiotic, adrenal glucocorticoid, epinephrine or pharmaceutically acceptable salts thereof in a weight ratio of (1-8):(2-5):(0.00005-0.001). The pharmaceutical composition provided can be used for treatment of vascular diseases and tumors.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: February 19, 2019
    Assignees: GUANGZHOU YIDAI PHARMACEUTICAL CO., LTD., SUN YAT-SEN UNIVERSITY
    Inventors: Hua Wang, Huanchun Liang
  • Patent number: 10188738
    Abstract: The present application provides a pharmaceutical formulation comprising a folate receptor (FR)-targeting antineoplastic substance or composition, wherein the pharmaceutical formulation is configured for administration by inhalation, wherein the FR-targeting antineoplastic substance or composition is comprised in a nanoparticle and wherein the nanoparticles are comprised in microparticles, and its use in the treatment of a proliferative disease affecting at least part of the respiratory tract. The present application further provides a pharmaceutical formulation comprising an antineoplastic agent and a FR-targeting excipient, for use in the treatment of a proliferative disease affecting at least part of the respiratory tract.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: January 29, 2019
    Assignee: Université Libre de Bruxelles
    Inventors: Karim Amighi, Rémi Rosière, Nathalie Wauthoz, Michel Gelbecke
  • Patent number: 10183033
    Abstract: The invention provides compounds of formula I: or a salt thereof. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods using the compounds of formula I.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: January 22, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Ingrid Gunda Georg, Satish Prakash Patil, Ashok K. Saluja, Rohit Chugh, Selwyn M. Vickers
  • Patent number: 10100090
    Abstract: In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators with the ClpP endopeptidase; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of search in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 16, 2018
    Assignee: St. Jude Children's Research Hospital
    Inventors: Richard E. Lee, Ying Zhao, Liu Jiuyu
  • Patent number: 10092596
    Abstract: The present invention provides compositions of therapeutic agents and methods of use for reducing and/or treating gastrointestinal inflammation. In particular aspects, the tungstate salts described herein and pharmaceutical compositions thereof inhibit the activity of one or a plurality of anaerobic respiratory enzymes in facultative anaerobic bacteria such as, for example, Enterobacteriaceae, that can exacerbate inflammation. In particular embodiments, the present invention provides compositions of therapeutic agents for treating gastrointestinal inflammation, as well as methods for treating or preventing gut microbial imbalance due to an increase in the abundance of intestinal Enterobacteriaceae.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: October 9, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Andreas J. Baumler, Sebastian E. Winter
  • Patent number: 10080876
    Abstract: Described here are devices, systems, and kits for delivering substances to tissues. The devices generally include one or more chambers (102) and a reservoir (108) within each chamber. The reservoir may locally deliver a microdose amount of a substance to a target tissue. In some variations, a microdose amount is used in early human studies, e.g., before a phase I clinical trial, to evaluate the effect of the substance on a target tissue, or to obtain pharmacokinetic or metabolic data. In other variations, a microdose amount is used to locally treat a medical condition. In yet other variations, a microdose amount is used to locally deliver a contrast agent for a structural or functional imaging procedure. Methods for delivering and retrieving the devices from the target tissue are also described.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: September 25, 2018
    Assignee: Kibur Medical, Inc.
    Inventors: Robert I. Tepper, Russell Hirsch, Jason E. Fuller, Jessica L. Duda, Craig Muir, Jeffrey S. Ross, J. Christopher Flaherty
  • Patent number: 10023581
    Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: July 17, 2018
    Assignees: The Regents of the University of California, Vybyl Holdings, Inc.
    Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L. M. LeGuyader, Paul A. Bertin
  • Patent number: 9993458
    Abstract: Systems and methods for determining whether a cancer patient may respond to inhibition of RNA polymerase II as a treatment for the patient are provided. Inhibition of RNA polymerase II may be by way of chemotherapy with an agent such as triptolide, an analog of triptolide, or a prodrug form of triptolide. The cancer patient may be a pancreatic cancer patient, an ovarian cancer patient, a gastric cancer patient, or an esophageal cancer patient. The patient may have any cancer in which c-Myc is over-expressed or over-amplified.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: June 12, 2018
    Assignees: Institute For Cancer Research, NexusPharma, Inc.
    Inventors: Igor Astsaturov, Vladimir Khazak, Ilya Serebriiski
  • Patent number: 9943502
    Abstract: The present invention includes compositions and methods for the treatment of cancer comprising an antineoplastic drug and an inhibitor of chromosome maintenance region 1 (CRM1) protein expression or activity, wherein the inhibitor of CRM1 enhances the anti-neoplastic effect of the antineoplastic drug.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: April 17, 2018
    Assignee: Texas Tech University System
    Inventor: Weimin Gao
  • Patent number: 9926287
    Abstract: A method of crystallizing docetaxel is disclosed. The method comprises (a) combining docetaxel and at least one solubilizing solvent to obtain a solution, wherein the solubilizing solvent is selected from the group consisting of acetone, methyl-tert-butyl ether, tetrahydrofuran (THF), and acetonitrile and (b) adding an anti-solvent to the solution to obtain a crystalline docetaxel, wherein the anti-solvent is water.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: March 27, 2018
    Assignee: Phyton Holdings, LLC
    Inventors: Brian A. Bucher, Edward M. Desimone, III, Roland R. Franke, Rex T. Gallagher, Barry J. Hand, Christopher D. Howe, James H. Johnson, John S. Juchum, Marc A. Plante, T.G. Sambandam, Dong S. Yang
  • Patent number: 9914956
    Abstract: Provided herein are novel irreversible sialidase inhibitors. These compounds can be conjugated with a detectable tagging moiety such as azide-annexed biotin via CuAAC for isolation and identification of sialidases. The provided compounds and the corresponding detectable conjugates are useful for detecting sialidase-containing pathogens and imaging in situ sialidase activities under physiological conditions.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: March 13, 2018
    Assignee: Academia Sinica
    Inventors: Chi-Huey Wong, Jim-Min Fang, Yih-Shyun E. Cheng, Charng-Sheng Tsai
  • Patent number: 9877923
    Abstract: The present disclosure generally relates to a process for preparing therapeutic nanoparticles, where the process includes combining a therapeutic agent with an organic acid. The therapeutic nanoparticles may have, for example, improved drug loading and/or drug release properties.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: January 30, 2018
    Assignee: Pfizer Inc.
    Inventors: Maria Figueiredo, Erick Peeke, David Dewitt, Christina Van Geen Hoven, Greg Troiano, James Wright, Young-Ho Song, Hong Wang
  • Patent number: 9878486
    Abstract: An in situ method to deploy and/or plasticize a shape-memory material in order to change the material's physical dimensions and/or mechanical properties, includes a method for deploying a shape memory polymer having a deformed or compressed shape in an environment at a first temperature, the shape memory polymer having a first glass transition temperature which is greater than the first temperature. The method also includes contacting the shape memory polymer with an activation fluid in an amount effective to decrease the glass transition temperature of the shape memory polymer from the first glass transition temperature to a second glass transition temperature which is less than or equal to the first temperature, where the activation fluid comprises a sugar present in an amount effective to raise a flash point of the activation fluid.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: January 30, 2018
    Assignee: Baker Hughes, a GE company, LLC
    Inventors: Bairu Liu, Anil Sadana, James B. Crews
  • Patent number: 9764065
    Abstract: Medical devices are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the therapeutic agent is not enclosed in micelles or encapsulated in particles or controlled release carriers.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: September 19, 2017
    Assignee: Lutonix, Inc.
    Inventor: Lixiao Wang
  • Patent number: 9763880
    Abstract: Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: September 19, 2017
    Assignee: Teikoku Pharma USA, Inc.
    Inventor: Kiichiro Nabeta
  • Patent number: 9707206
    Abstract: Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided. Some embodiments relate to dosage forms. Dosage forms can include an aqueous pharmaceutical composition containing (i) from about 2% to about 6% by weight of cromolyn sodium, and (ii) an osmolarity adjusting agent consisting of (A) between about 0.1% to about 0.5% by weight of sodium chloride, inclusive of the endpoints, and (B) optionally salts of EDTA; and an inhalation device that forms an aerosol of said pharmaceutical composition, said aerosol exhibiting a respirable fraction of said pharmaceutical composition (<5 ?m) as measured by USP <1601> of at least about 60%, are provided.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: July 18, 2017
    Assignee: Patara Pharma, LLC
    Inventors: William Gerhart, Manfred Keller, Ahmet Tutuncu, Pravin Soni
  • Patent number: 9655876
    Abstract: A liquid composition which includes a taxane-based active ingredient (a) selected from the group consisting of docetaxel and a derivative thereof; at least one glycol (b); and at least one surfactant component (c) selected from the group consisting of a polysorbate, a polyoxyethylene glycol ester, and a polyoxyethylene castor oil derivative, in which a volume ratio of the glycol (b) to the surfactant component (c) is in a range of form 45/55 to 55/45, and a total content of the glycol (b) and the surfactant component (c) with respect to a total volume of the liquid composition is 95% (v/v) or more.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: May 23, 2017
    Assignee: FUJIFILM Corporation
    Inventor: Shirou Sonoke
  • Patent number: 9567312
    Abstract: The invention provides new cabazitaxel isoserine ester intermediates and new synthetic methods, and a preparation method for the anti-tumour drugs cabazitaxel, docetaxel and paclitaxel from the new cabazitaxel isoserine intermediates.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: February 14, 2017
    Inventors: Yunman Zheng, Tianhui Xu, Ragina Naidu
  • Patent number: 9539234
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: January 10, 2017
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Patent number: 9527825
    Abstract: Disclosed is a method of crystallizing docetaxel comprising combining docetaxel and at least one solubilizing solvent to obtain a solution, wherein the solubilizing solvent is methylene chloride and adding an anti-solvent to the solution to obtain a crystalline docetaxel, wherein the anti-solvent is water.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: December 27, 2016
    Assignee: Phyton Holdings, LLC
    Inventors: Brian A. Bucher, Edward M. Desimone, III, Roland R. Franke, Rex T. Gallagher, Barry J. Hand, Christopher D. Howe, James H. Johnson, John S. Juchum, Marc A. Plante, T. G. Sambandam, Dong S. Yang
  • Patent number: 9522164
    Abstract: Compositions and methods for the treatment of cancer are provided.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: December 20, 2016
    Assignee: LANKENAU INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Iraimoudi S. Ayene, George C. Prendergast
  • Patent number: 9498443
    Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising a sugar, a cyclodextrin, and polymeric nanoparticles comprising a copolymer and a therapeutic agent which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: November 22, 2016
    Assignee: Pfizer Inc.
    Inventors: Greg Troiano, Young-Ho Song, Stephen E. Zale, James Wright, Christina Van Geen Hoven
  • Patent number: 9446020
    Abstract: The present invention relates to compositions and methods to modulate ?-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: September 20, 2016
    Assignee: Blanchette Rockefeller Neurosciences Institute
    Inventors: Rene Etcheberrigaray, Daniel L. Alkon
  • Patent number: 9393318
    Abstract: The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: July 19, 2016
    Assignee: ABRAXIS BIOSCIENCE, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong
  • Patent number: 9339553
    Abstract: A liquid composition of an insoluble medicament and a preparation method thereof are disclosed. The composition includes insoluble medicament, oil for injection, phospholipid, and solvent; the percentage by weight of each component is as follows: insoluble medicament 0.01-10%, oil for injection 0%-20%, phospholipid 10-80%, solvent 20-89%. The preparation method for the composition includes the following steps: dissolving an insoluble medicament into solvent or oil for injection or a mixture thereof firstly, and then adding other components, and mixing uniformly; or dissolving an insoluble medicament into a mixture of other components, and mixing uniformly; or dissolving an insoluble medicament into part of solvent firstly, and then adding into a mixed solvent of other components and the remaining solvent, and mixing uniformly.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: May 17, 2016
    Assignee: PEKING UNIVERSITY
    Inventors: Qiang Zhang, Wenbing Dai, Jiancheng Wang, Xuan Zhang
  • Patent number: 9326979
    Abstract: An object of the invention is to provide a transdermal absorption preparation capable of sustaining the blood morphine concentration at an effective level over at least 48 hours, etc.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: May 3, 2016
    Assignee: TEIKA PHARMACEUTICAL CO., LTD.
    Inventors: Takahito Kimura, Masahiro Orihashi, Shigeto Fujishita, Koichi Takabatake, Tatsuhisa Kato, Satoshi Shiota, Yuichiro Shima